Enterprise Value

3.484B

Cash

889.2M

Avg Qtr Burn

N/A

Short % of Float

4.42%

Insider Ownership

1.64%

Institutional Own.

-

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vivitrol (naltrexone) Details
Alcohol dependence, Opioid dependence

Approved

Quarterly sales

Aristada (aripiprazole lauroxil) Details
Mental health, Schizophrenia

Approved

Quarterly sales

LYBALVI (ALKS 3831) Details
Bipolar disease, Mental health, Schizophrenia

Approved

Quarterly sales

Nemvaleukin alfa (ALKS-4230) (IL-2) + KEYTRUDA (PD-1) Details
Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer

Phase 3

Update

Phase 2

Update

ALKS 2680 (RDC-264177) ( Orexin 2 Receptor Agonist) Details
EDS in Idiopathic Hypersomnia , Narcolepsy

Phase 1

Data readout

Failed

Discontinued